After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
MarketWatchPaywall
Read Full Article at MarketWatch →Ad Slot — In-Article (728x90)
Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.
This is a summary. For the full story, read the original article at MarketWatch.
Original source: MarketWatch